Other Converted Paper Product Manufacturing (U.S.) — NAICS 32229

An investor's rollup primer. NAICS (North American Industry Classification System) is the U.S. government's standard industry-coding system; 32229 is the five-digit "industry" that groups two more detailed child industries — 322291 (sanitary paper) and 322299 (all other converted paper). This primer synthesizes the two child primers plus our federal ground-truth statistics for the combined level.

1. Overview

This industry is the "converting" end of the paper business that has nothing to do with boxes, bags, or writing paper. It takes finished paper, paperboard, or wet wood pulp and shapes it into two very different families of everyday product: hygiene paper you use on your body or in the bathroom (toilet paper, paper towels, facial tissue, napkins, diapers, tampons, pads) and molded/converted paper goods you use around food and shipping (egg cartons, paper plates and trays, coffee filters, protective packaging, plus legacy items like cigarette paper and gift wrap).

What ties the two halves together for an investor is a shared economic DNA: both are converting businesses that buy fiber and sell finished product, both live on the thin spread between input cost and selling price, both are freight-sensitive (bulky, low-value products ship poorly, so plants sit near demand), and both are hard to own cleanly in U.S. public markets — the biggest and best-positioned players are diversified giants, private, private-equity-owned, or listed overseas.

But the two halves point in different directions, and that contrast is the real story of this level. One (sanitary paper) is a large, concentrated, defensive consumer-staples business fought over by a few global brand owners, growing at a low-single-digit crawl. The other (all-other converted paper) is a small, fragmented, private/PE-owned packaging business riding a genuine growth tailwind as plastic and foam get banned in favor of fiber. Lead with the contrast; then read the combined figures.

2. What's inside — the two child industries and how they differ

The 32229 level is not a single homogeneous market. It is a large, mature hygiene business bolted to a small, growing packaging business. The comparison below is where an allocator should start.

The single sharpest contrast is in the middle two rows: sanitary paper is 72% of the revenue from only 29% of the plants — a handful of very large, integrated lines — while all-other converted paper is the mirror image, 28% of revenue spread across 71% of the plants as small independent converters. One is concentrated and brand-driven; the other is fragmented and commodity-driven. The federal concentration numbers for the combined level (Section 3) are simply a weighted blend of an oligopoly and a scrum.

Where the boundary sits. Both children exclude the upstream mills that make paper and paperboard (NAICS 322110/322120/322130) and the box/bag/envelope codes (the 32221x group, 322220, 322230). If it is a box, a bag, an envelope, or writing paper, it is not in 32229. If it is a paper towel or a molded egg carton, it is.

3. Size — the combined level

Federal statistics for NAICS 32229 (our ground-truth figures):

The HHI (a single 0–10,000 concentration score) is suppressed at this level in the federal data, so we do not state one. The all-other converted paper child (322299) has an HHI of just 165.5 — very low — while the sanitary-paper child's HHI is suppressed. [4]

How the children add up. The rollup is dominated by sanitary paper. Of the $19.7 billion in receipts, roughly $14.1 billion (72%) is sanitary paper and $5.59 billion (28%) is all-other converted paper [3][4]. The physical counts tie out almost exactly to the children: establishments (138 + 331 = 469) and employment (19,445 + 12,827 = 32,272) sum precisely, and payroll (~$1.40B + ~$0.76B ≈ $2.16B) and receipts (~$14.1B + ~$5.59B ≈ $19.7B) match to rounding [2][3][4]. (The firm count is the one place they don't sum: 100 + 318 = 418 versus the 412 reported for the level, because the Economic Census de-duplicates firms that operate in both children.)

A capital-intensive, blue-collar industry. With 412 firms and 469 plants producing $19.7 billion, the level averages about $610,000 of shipments per worker and pays roughly $67,000 per employee — but that average hides the split: sanitary-paper lines run about $726,000 of output per worker at ~$72K pay, versus ~$436,000 per worker at ~$59K in the fragmented converting half [3][4].

Undercount and definition caveats. This is a corporate manufacturing industry, not one hidden in informal or micro-operators, so the usual federal undercount is mild. The real caveats are different:

1. Classification, not missing plants. Census assigns each plant to a single NAICS code by its primary product. Vertically integrated tissue makers that also run pulp/tissue mills land in the upstream mill codes, and diversified packaging plants that mold some egg cartons are counted under their main code — so the value chain around 32229 is larger than the $19.7 billion line, and the investable footprint is more understated than the plant count suggests [3][4].
2. Factory-gate, not retail. These are shipment values at the plant, not consumer/retail sales. Commercial "market size" reports for toilet paper or molded fiber use retail boundaries and are not comparable to this number.
3. Mixed vintages. Receipts and concentration are 2022; employment and payroll are 2023 — close, but not a single snapshot.
4. Imports excluded. Domestic shipments don't capture imports; bulky products (tissue, egg cartons) trade locally, but dense items (coffee filters, cigarette paper, novelties) face more import competition.

4. Investable universe — where value concentrates across the children

The most important fact for a public-market investor spans both children: there is no large U.S.-listed pure-play in either half of 32229. Where you can put capital depends on which half you want.

In sanitary paper (the 72% of revenue), the exposure is large but diluted inside diversified staples giants:

In all-other converted paper (the 28%), the U.S. public universe has been hollowed out entirely; the ownable names are foreign or private:

The takeaway across both children: the cleanest large-cap way into this level is P&G or Kimberly-Clark — but you are buying a diversified consumer-staples company where 32229 is one segment, not the whole story. The purer plays (Cascades, Essity, KP Tissue, Hartmann, Huhtamaki) are all foreign-listed, and the fastest-growing assets (private-label tissue, sustainable molded fiber) sit in private and PE hands. Screener traps to avoid: Clearwater Paper (CLW) exited tissue in 2024 (at ~6× trailing adjusted EBITDA), UFP Technologies (UFPT) sold molded fiber to CKF for ~$32 million in 2022 and is now ~92% medical devices, and Mativ (MATV) sold its cigarette-paper business for $620 million in 2023 — none is still a play here [6][10][19].

5. How the money works

Both children run the same core equation: owners earn the spread between the cost of input fiber and the selling price of finished product, minus energy, labor, and freight, through capital-intensive plants that must run full. The differences are in the details.

• Input costs differ by half. Sanitary paper swings on wood pulp — northern bleached softwood kraft ("NBSK") is the key cost; when pulp spikes, converter margins compress unless price increases stick [18]. The all-other half runs more on recovered paper (old newspaper and old corrugated cardboard) plus the energy to dry molded pulp — a technical review estimates drying can require 8–20× the energy used in initial vacuum forming [4]. In both, cost pass-through happens with a lag, so margins compress on the way up and recover on the way down.
• Volume vs. price. In sanitary paper, volumes barely move with the economy (people don't stop buying toilet paper), so growth comes from price and mix, not units — the 2021–2023 inflation, when the majors pushed list-price increases and cut sheet counts ("shrinkflation"), is the clearest demonstration [7][18]. In all-other converted paper, volume genuinely grows as plastic and foam get banned, so the story there is unit growth on thin margins.
• Freight economics keep both regional. Finished tissue and egg cartons are bulky and low-value-per-truck, so production sits near demand and scale advantage comes from integrated mills (tissue) or distribution and large-account service (molded fiber) rather than the factory floor [14][18].
• Brand premium vs. private label. Sanitary paper has a branded tier (Charmin, Kleenex, Huggies) that commands premium pricing and heavy advertising, plus a growing private-label/away-from-home ("AfH") tier that competes on price — mid-size producers' tissue share rose from ~27% (2007) to ~33% recently [18]. All-other converted paper is mostly commodity private-label with a thin specialty tier (engineered protective packaging, branded coffee filters) that earns higher margins on technical know-how [4].
• Tariff and trade exposure. Even locally manufactured products retain exposure to imported materials and equipment. Kimberly-Clark reported approximately $100 million of incremental tariff-related costs in 2025, primarily in North America [8].
• What investors watch. For the public staples names: organic sales growth (price + volume/mix), gross/operating margin, free cash flow, and dividends — PG and KMB are long-standing dividend payers [7]. For the private/PE side: capacity utilization, fiber-cost pass-through, and volume tied to regulatory substitution.

6. Demand drivers

Because the level blends two markets, its demand drivers pull in different directions:

• Population and household formation set the steady baseline for tissue and towels (defensive, staple demand) [3].
• Births drive diapers — the falling U.S. birth rate is a structural headwind the majors offset with premium products [7]. Partly offsetting it, an aging population drives adult incontinence, a genuine growth pocket [8].
• The plastic-and-foam substitution tailwind is the big one for the all-other half: state bans on expanded-polystyrene ("Styrofoam") foodware — now ~12 states, including California's SB 54 — plus PFAS ("forever chemical") coating bans push buyers from plastic and foam toward molded fiber [15]. Independent analysts project mid-single-digit-plus growth in molded fiber through the early 2030s (forecasts, not guarantees) [16].
• Egg production and the cage-free transition drive carton demand; the 2024–25 avian-flu (HPAI) outbreaks culled tens of millions of layers — U.S. table-egg production declined 4% to 90.1 billion eggs in 2025 — crimping carton volumes while raising prices [20]. The shift to cage-free (~40% of layers) is upgrading carton specifications [20].
• Away-from-home activity (offices, hotels, dining, travel) drives AfH tissue; hybrid work remains a drag on that channel [18].
• Foodservice, takeout, and e-commerce lift plates, trays, and protective molded fiber [15].
• Secular declines weigh on legacy niches: cigarette/rolling paper (falling smoking) and gift wrap/party novelties (digital greetings) [6][17].

7. Regulation

Regulation is uneven across the level — a compliance cost in places, a powerful demand tailwind in others.

• Feminine care is medical-device territory. Tampons and pads are regulated by the U.S. Food and Drug Administration (FDA) as medical devices, with premarket clearance and Toxic Shock Syndrome warning labeling; FDA issued draft guidance on menstrual-product testing and labeling in October 2025 [15].
• PFAS is the shared thread — and it cuts both ways. In the sanitary half, states are banning intentionally added PFAS in menstrual products — Vermont passed a ban in 2024 (effective January 2026) and California restricts PFAS as well — a reformulation and litigation risk [15]. In the all-other half, FDA confirmed grease-proofing PFAS are no longer sold into the U.S. food-packaging market (Feb 2024) and determined that 35 food-contact notifications were no longer effective (January 2025), forcing molded-fiber makers to reformulate with fluorine-free barriers — a cost, but one that cements fiber's "clean" positioning [15].
• Plastic/EPS bans and Extended Producer Responsibility (EPR). State foam bans and packaging-EPR laws (now in seven states as of December 2025) shift cost onto plastic and favor recyclable/compostable fiber — a net positive for the all-other half [15].
• Ordinary consumer-product rules cover toilet paper, towels, tissue, and diapers (general product safety, not FDA clearance); FDA food-contact rules cover plates, trays, and cartons.
• Forestry and environmental pressure. EPA wastewater rules at pulp/tissue mills, forest-certification expectations (e.g., FSC), and FTC "Green Guides" on eco-claims apply across the level; advocacy campaigns over virgin-fiber sourcing target the tissue majors [18]. The American Forest & Paper Association reports that 90% of U.S. tissue manufacturers use some recycled paper and that tissue producers consumed approximately 3.8 million tons of recycled paper in 2024 [18].

8. Consolidation

Both children are consolidating, but from opposite starting points — and the through-line is assets migrating out of U.S. public markets into private, PE, and foreign hands.

• Sanitary paper: an oligopoly diversifying and a rising mid-tier. At the top, P&G, Kimberly-Clark, and Georgia-Pacific dominate at-home shelves, collectively holding roughly 60% of North American tissue capacity [7][11]. Two recent moves reshaped the field: Sofidel bought Clearwater Paper's private-label tissue business (~$1.06B, Nov 2024), adding four U.S. plants, approximately 1,700 employees, and 340,000 metric tons of annual capacity — vaulting to #4 in North America and pulling a U.S. public company out of tissue entirely [10]; and Kimberly-Clark agreed to acquire Kenvue (~$48.7B, Nov 2025) — the #2 hygiene player pivoting toward consumer health and away from mature paper [9]. Mid-size producers' tissue share rose from ~27% (2007) to ~33%, led by investment from First Quality, Kruger, Sofidel, and Irving [18].
• All-other converted paper: PE roll-ups in a fragmented field. With an HHI of 165.5 and a top-4 share under 18%, no one is close to dominant [4] — yet Apollo's Novolex absorbed Pactiv Evergreen ($6.7B, April 2025), paying $18.00 per share and delisting the stock, while foreign strategics (Huhtamaki, Hartmann) keep building U.S. capacity, and public exits (Mativ's tobacco papers, UFP's molded fiber, CSS to IG Design) point the same way [6][12][14][17][19].

The combined signal: the interesting competitive action — private-label tissue share gains and sustainable molded-fiber growth — is being captured largely off the U.S. public exchanges.

9. Risks

• Input-cost and margin volatility — pulp (tissue), recovered fiber (molded), energy, and freight can squeeze thin margins fast when pass-through lags [18].
• Private-label trade-down and retailer power — Walmart, Amazon, Costco store brands pressure branded pricing across both halves [18].
• Declining U.S. births erode diaper volume over time [7].
• Hybrid work is a structural drag on the away-from-home tissue channel [18].
• Regulatory and chemical exposure — PFAS bans and tampon-safety scrutiny raise reformulation costs and class-action risk (sanitary); PFAS reformulation adds cost even as it helps demand (molded fiber) [15].
• Tariff and trade exposure — even locally manufactured products face imported-material and equipment costs; Kimberly-Clark reported ~$100M of incremental tariff-related costs in 2025 [8].
• Egg-market and avian-flu shocks can whipsaw carton volumes — U.S. table-egg production declined 4% in 2025 [20].
• Feedstock transition — declining print circulation is reducing availability of recovered newspaper for molded fiber [4].
• Secular declines in cigarette/rolling paper and gift/party novelties [6][17].
• Operational risks — fires, machine outages, sole-source components, labor shortages; skilled maintenance labor is especially important because a small loss of uptime can materially reduce absorption of fixed costs [8].
• Low organic growth and capital intensity — the sanitary half leans on price when volume won't grow; the molded half must keep expensive lines full.
• Currency and foreign-market risk for the globally diversified public names and the only purer plays (Essity, Huhtamaki, Hartmann, IG Design) [7].

10. How to invest and the outlook

Public-market routes (limited across both children).

• Sanitary paper: the main large-cap ways in are Procter & Gamble (NYSE: PG) and Kimberly-Clark (NASDAQ: KMB) — diversified staples stocks with long dividend histories where sanitary paper is a meaningful segment, not the whole company; KMB's profile is shifting with the pending Kenvue deal [7][9]. Purer exposure means foreign listings: Cascades (TSX: CAS), Essity (Stockholm: ESSITY-B), KP Tissue (TSX: KPT) [18].
• All-other converted paper: no U.S. pure-play. The honest options are foreign-listed — Huhtamaki (Helsinki), Brødrene Hartmann (Copenhagen) as the closest pure bet, IG Design Group (London AIM) [13][14][17].
• Broad consumer-staples index funds hold PG and KMB and give indirect, diversified exposure without single-stock risk.
• Screener traps: Clearwater Paper (CLW), UFP Technologies (UFPT), and Mativ (MATV) have all exited their relevant businesses [6][10][19].

Private routes (where the real exposure is). Both halves point private for the purest and fastest-growing assets: private-label tissue and AfH converters (First Quality, Sofidel, regional mills) on the sanitary side, and molded-fiber/foodservice operators (Novolex/Pactiv Evergreen, Genpak, Sabert, Rockline coffee filters) on the all-other side. PE and strategic M&A — not IPOs — has been the dominant liquidity path across the level [10][12]. Underwriting should be plant-by-plant: machine age and technology, fiber sourcing, customer concentration, freight radius, energy contracts, maintenance backlog, dryer age and efficiency, contract terms, environmental liabilities, and true sustainable throughput. The Clearwater tissue sale at ~6× trailing adjusted EBITDA provides one private-market transaction reference [10].

Outlook (forward-looking judgment). Treat 32229 as two speeds under one code. The 72% that is sanitary paper is a defensive, low-single-digit-growth staple where value is created through price/mix, cost control, and consolidation — a diaper headwind from falling births partly offset by an aging-driven incontinence tailwind. The 28% that is all-other converted paper is a mid-single-digit-growth substitution story as plastic and foam give way to fiber. The tension for a public-market investor is identical in both halves: the growth and the purest exposures are real, but the clean U.S. listings largely aren't there — so capturing this level means owning diversified large-caps for a slice, going overseas, or going private. Near-term swing factors to watch: pulp and energy prices, the pace of AfH recovery, whether private label keeps gaining tissue share, the KMB–Kenvue integration, PFAS/tampon reformulation timelines, tariff developments, egg-market volatility, and the shift toward recycled and alternative fibers.

---

Sources

1. U.S. Census Bureau. 2022 Economic Census — Concentration Ratios and Selected Statistics, NAICS 32229 (receipts, firm count, CR4/CR8/CR20/CR50, HHI). 2022. (Histometrics ground-truth dataset.) https://www.census.gov/programs-surveys/economic-census.html
2. U.S. Census Bureau. 2023 County Business Patterns, NAICS 32229 (establishments, employment, annual payroll). 2023. (Histometrics ground-truth dataset.) https://www.census.gov/programs-surveys/cbp.html
3. U.S. Census Bureau. 2022 Economic Census — Selected Statistics, NAICS 322291 (Sanitary Paper Product Manufacturing). 2022. https://www.census.gov/programs-surveys/economic-census.html
4. U.S. Census Bureau. 2022 Economic Census — Selected Statistics, NAICS 322299 (All Other Converted Paper Product Manufacturing). 2022. https://www.census.gov/programs-surveys/economic-census.html
5. U.S. Small Business Administration. Table of Small Business Size Standards. 2023. https://www.sba.gov/document/support-table-size-standards
6. Global Atlanta / Mativ Investor Relations. Mativ Announces Sale of Engineered Papers (Schweitzer-Mauduit) Business for $620 Million. 2023. https://ir.mativ.com/news/news-details/2023/Mativ-Announces-Proposed-Sale-of-Engineered-Papers-Business-for-620-Million/default.aspx
7. Procter & Gamble Investor Relations. P&G Announces Fourth Quarter and Fiscal Year 2025 Results and Form 10-K FY2025. 2025. https://www.pginvestor.com/
8. U.S. Securities and Exchange Commission. Kimberly-Clark Corp — Form 10-K, FY2025. 2025. https://www.sec.gov/Archives/edgar/data/55785/000162828026007567/kmb-20251231.htm
9. CNBC. Kimberly-Clark agrees to buy Tylenol owner Kenvue in $48.7 billion deal. 2025. https://www.cnbc.com/2025/11/03/kimberly-clark-to-buy-kenvue.html
10. Packaging Dive. Clearwater closes $1B sale of tissue business to Sofidel. 2024; Clearwater Paper Corporation press release (sale at ~6× trailing adjusted EBITDA). https://www.packagingdive.com/news/clearwater-sell-tissue-business-sofidel-paperboard/721956/
11. Wikipedia / Koch, Inc. Georgia-Pacific (Koch subsidiary; largest North American tissue producer). 2025. https://en.wikipedia.org/wiki/Georgia-Pacific
12. Packaging Dive. Novolex Completes $6.7B Acquisition of Pactiv Evergreen. 2025; Pactiv Evergreen Form 8-K ($18.00 per share, April 1, 2025). https://www.packagingdive.com/news/novolex-closes-acquisition-pactiv-evergreen/744049/
13. Huhtamaki. Chinet Molded-Fiber Tableware — North America; Fiber-Based Egg Cartons Made from 100% Recycled Materials. 2024. https://www.huhtamaki.com/en-us/north-america/retail/the-chinet-brand/
14. Missouri Partnership / Packaging Strategies. Brødrene Hartmann Molded-Fiber Egg-Carton Plant, Rolla, Missouri; 2024–25 North American Expansion. 2016; 2024. https://missouripartnership.com/global-food-packaging-manufacturer-selects-rolla-for-its-first-u-s-location/
15. U.S. Food and Drug Administration. Menstrual Product Safety / Tampons; PFAS Grease-Proofing Agents No Longer Sold in the U.S.; 35 Food-Contact Notifications No Longer Effective (January 2025); state PFAS and EPS-foam packaging bans (California SB 54); EPR laws (seven states as of December 2025). 2024–2025. https://www.fda.gov/
16. Mordor Intelligence / Coherent Market Insights. Molded Fiber Egg Carton and Molded Fiber Pulp Packaging Market Size & Growth. 2025–2026. https://www.mordorintelligence.com/industry-reports/molded-fiber-egg-carton-market
17. Nasdaq / IG Design Group. IG Design Group Acquires CSS Industries (~$88M). 2020. https://www.nasdaq.com/press-release/css-industries-announces-acquisition-by-ig-design-group-plc-2020-01-20
18. Tissue Online North America. Competition intensifies in the U.S. tissue paper market (private-label and mid-size share, capacity, pulp costs); Cascades/Essity/KP Tissue profiles; American Forest & Paper Association tissue recycling data. 2025. https://tissueonlinenorthamerica.com/competition-intensifies-in-u-s-tissue-paper-market/
19. UFP Technologies / Wikipedia. UFP sold Molded Fiber business to CKF, Inc. (~$32 million, 2022); company now ~92% MedTech. 2022–2025. https://en.wikipedia.org/wiki/UFP_Technologies
20. USDA National Agricultural Statistics Service. Chickens and Eggs 2025 Summary (Table-Egg Production: 90.1 Billion Eggs, −4%; ~40% cage-free). 2025. https://www.nass.usda.gov/Publications/Todays_Reports/reports/ckegan26.pdf